Navann Ty
Stock Analyst at Exane BNP Paribas
(3.24)
# 2,478
Out of 4,994 analysts
39
Total ratings
55.6%
Success rate
7.1%
Average return
Main Sectors:
Stocks Rated by Navann Ty
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OGN Organon & Co. | Downgraded: Hold | $15 → $14 | $13.70 | +2.23% | 6 | Apr 28, 2026 | |
| MDLN Medline | Initiated Coverage: Hold | $38 | $34.00 | +11.76% | 1 | Jan 12, 2026 | |
| NTRA Natera | Upgraded: Hold | $28 → $172 | $388.33 | -55.71% | 2 | Oct 27, 2025 | |
| GEHC GE HealthCare Technologies | Reiterated: Buy | $92 | $66.23 | n/a | 1 | Sep 10, 2025 | |
| PAHC Phibro Animal Health | Reiterated: Hold | $24 → $37 | $35.38 | n/a | 2 | Sep 4, 2025 | |
| COO The Cooper Companies | Upgraded: Buy | $92 | $55.13 | n/a | 1 | Jul 22, 2025 | |
| KVUE Kenvue | Initiated Coverage: Hold | $28 | $17.85 | n/a | 1 | May 30, 2023 | |
| SKIN SkinHealth Systems | Upgraded: Hold | n/a | $0.6703 | n/a | 2 | Mar 20, 2023 | |
| ABBV AbbVie | Initiated Coverage: Hold | $169 | $265.00 | n/a | 1 | Dec 8, 2022 | |
| EOLS Evolus | Initiated Coverage: Buy | $13 | $8.18 | n/a | 1 | Dec 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $22 → $26 | $44.22 | n/a | 2 | Mar 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $16 → $11 | $17.03 | n/a | 2 | Mar 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $232 → $208 | $72.44 | n/a | 6 | Mar 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $200 | $240.92 | n/a | 1 | Oct 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $39 → $42 | $22.94 | n/a | 6 | May 17, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $36.39 → $51.79 | $8.11 | n/a | 3 | Mar 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | $10 | $39.19 | n/a | 1 | Apr 24, 2020 |
Organon & Co.
Apr 28, 2026
Downgraded: Hold
Price Target: $15 → $14
Current: $13.70
Upside: +2.23%
Medline
Jan 12, 2026
Initiated Coverage: Hold
Price Target: $38
Current: $34.00
Upside: +11.76%
Natera
Oct 27, 2025
Upgraded: Hold
Price Target: $28 → $172
Current: $388.33
Upside: -55.71%
GE HealthCare Technologies
Sep 10, 2025
Reiterated: Buy
Price Target: $92
Current: $66.23
Upside: n/a
Phibro Animal Health
Sep 4, 2025
Reiterated: Hold
Price Target: $24 → $37
Current: $35.38
Upside: n/a
The Cooper Companies
Jul 22, 2025
Upgraded: Buy
Price Target: $92
Current: $55.13
Upside: n/a
Kenvue
May 30, 2023
Initiated Coverage: Hold
Price Target: $28
Current: $17.85
Upside: n/a
SkinHealth Systems
Mar 20, 2023
Upgraded: Hold
Price Target: n/a
Current: $0.6703
Upside: n/a
AbbVie
Dec 8, 2022
Initiated Coverage: Hold
Price Target: $169
Current: $265.00
Upside: n/a
Evolus
Dec 8, 2022
Initiated Coverage: Buy
Price Target: $13
Current: $8.18
Upside: n/a
Mar 22, 2022
Reiterated: Hold
Price Target: $22 → $26
Current: $44.22
Upside: n/a
Mar 10, 2022
Reiterated: Hold
Price Target: $16 → $11
Current: $17.03
Upside: n/a
Mar 9, 2022
Reiterated: Hold
Price Target: $232 → $208
Current: $72.44
Upside: n/a
Oct 5, 2021
Initiated Coverage: Buy
Price Target: $200
Current: $240.92
Upside: n/a
May 17, 2021
Reiterated: Buy
Price Target: $39 → $42
Current: $22.94
Upside: n/a
Mar 2, 2021
Reiterated: Buy
Price Target: $36.39 → $51.79
Current: $8.11
Upside: n/a
Apr 24, 2020
Initiated Coverage: Hold
Price Target: $10
Current: $39.19
Upside: n/a